Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives
- PMID: 33025047
- PMCID: PMC7907037
- DOI: 10.1007/s00262-020-02735-0
Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives
Abstract
There has been a rapid progress in developing genetically engineered T cells in recent years both in basic and clinical cancer studies. Chimeric antigen receptor (CAR)-T cells exert an immune response against various cancers, including the non-small-cell lung cancer (NSCLC). As novel agents of immunotherapy, CAR-T cells show great promise for NSCLC. However, targeting specific antigens in NSCLC with engineered CAR-T cells is complicated because of a lack of tumor-specific antigens, the immunosuppressive tumor microenvironment, low levels of infiltration of CAR-T cells into tumor tissue, and tumor antigen escape. Meanwhile, the clinical application of CAR-T cells remains limited due to the cases of on-target/off-tumor and neurological toxicity, as well as cytokine release syndrome. Hence, optimal CAR-T-cell design against NSCLC is urgently needed. In this review, we describe the basic structure and generation of CAR-T cells and summarize the common tumor-associated antigens targeted in clinical trials on CAR-T-cell therapy for NSCLC, as well as point out current challenges and novel strategies. Although many obstacles remain, the new/next generation of CARs show much promise. Taken together, research on CAR-T cells for the treatment of NSCLC is underway and has yielded promising preliminary results both in basic and pre-clinical medicine. More pre-clinical experiments and clinical trials are, therefore, warranted.
Keywords: CAR-T-cell therapy; Future perspective; Immunotherapy; Non-small-cell lung cancer; Tumor microenvironment.
Conflict of interest statement
The author declares no competing financial interests.
Figures
Similar articles
-
Chimeric Antigen Receptor T-Cell Therapy in Lung Cancer: Potential and Challenges.Front Immunol. 2021 Nov 1;12:782775. doi: 10.3389/fimmu.2021.782775. eCollection 2021. Front Immunol. 2021. PMID: 34790207 Free PMC article. Review.
-
Chimeric antigen receptor-engineered T-cell therapy for liver cancer.Hepatobiliary Pancreat Dis Int. 2018 Aug;17(4):301-309. doi: 10.1016/j.hbpd.2018.05.005. Epub 2018 May 24. Hepatobiliary Pancreat Dis Int. 2018. PMID: 29861325 Review.
-
Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy.Front Med. 2019 Feb;13(1):57-68. doi: 10.1007/s11684-019-0683-y. Epub 2019 Feb 5. Front Med. 2019. PMID: 30721445
-
Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.Curr Res Transl Med. 2017 Sep;65(3):93-102. doi: 10.1016/j.retram.2017.08.003. Curr Res Transl Med. 2017. PMID: 28988742 Review.
-
Chimeric antigen receptor-modified T Cells inhibit the growth and metastases of established tissue factor-positive tumors in NOG mice.Oncotarget. 2017 Feb 7;8(6):9488-9499. doi: 10.18632/oncotarget.14367. Oncotarget. 2017. PMID: 28055955 Free PMC article.
Cited by
-
Evolving insights into the improvement of adoptive T-cell immunotherapy through PD-1/PD-L1 blockade in the clinical spectrum of lung cancer.Mol Cancer. 2024 Apr 24;23(1):80. doi: 10.1186/s12943-023-01926-4. Mol Cancer. 2024. PMID: 38659003 Free PMC article. Review.
-
Gut microbes as medical signature for the effectiveness of immunotherapy in patients with advanced non-small cell lung cancer.Aging Med (Milton). 2024 Feb 22;7(1):121-130. doi: 10.1002/agm2.12292. eCollection 2024 Feb. Aging Med (Milton). 2024. PMID: 38571678 Free PMC article. Review.
-
Chimeric Antigen Receptor (CAR)-T Cell Therapy for Non-Hodgkin's Lymphoma.Pathog Immun. 2024 Mar 15;9(1):1-17. doi: 10.20411/pai.v9i1.647. eCollection 2024. Pathog Immun. 2024. PMID: 38550613 Free PMC article. Review.
-
Paracrine Regulation and Immune System Pathways in the Inflammatory Tumor Microenvironment of Lung Cancer: Insights into Oncogenesis and Immunotherapeutic Strategies.Cancers (Basel). 2024 Mar 10;16(6):1113. doi: 10.3390/cancers16061113. Cancers (Basel). 2024. PMID: 38539448 Free PMC article. Review.
-
Current Situation and Prospect of Adoptive Cellular Immunotherapy for Malignancies.Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338231204198. doi: 10.1177/15330338231204198. Technol Cancer Res Treat. 2023. PMID: 38037341 Free PMC article. Review.
References
-
- Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Niksic M, Bonaventure A, Valkov M, Johnson CJ, Esteve J, Ogunbiyi OJ, Azevedo ESG, Chen WQ, Eser S, Engholm G, Stiller CA, Monnereau A, Woods RR, Visser O, Lim GH, Aitken J, Weir HK, Coleman MP, Group CW Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391(10125):1023–1075. doi: 10.1016/S0140-6736(17)33326-3. - DOI - PMC - PubMed
-
- Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, Cheng SYS, Bischoff HG, Peled N, Grossi F, Jennens RR, Reck M, Hui R, Garon EB, Boyer M, Rubio-Viqueira B, Novello S, Kurata T, Gray JE, Vida J, Wei Z, Yang J, Raftopoulos H, Pietanza MC, Garassino MC. Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer. N Engl J Med. 2018;378(22):2078–2092. doi: 10.1056/NEJMoa1801005. - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials